Eyes On Trials

Genetic differentiation across regions can significantly impact how populations respond to drugs. Variations in genetic makeup mean that a medication might be effective for one group but less so, or even harmful, for another. This variability underscores the importance of tailored clinical trials and has implications for the recent CDSCO notification on waiving clinical trials. Here, we’ll explore examples where genetic differences have influenced drug efficacy and safety, highlighting the importance of considering these differences in drug approval processes. Warfarin and Genetic Variability Case Study: Warfarin is a widely used anticoagulant prescribed to prevent blood clots. The drug's dosing is highly individualized, and genetic variations play a crucial role in how patients metabolize it. Variants in the CYP2C19 gene and the VKORC1 gene influence Warfarin’s effectiveness and risk of bleeding. Genetic Differentiation:In populations of European descent, certain genetic variants ...

Background: A Visionary Scientist's Mission: In the early 2000s, breast cancer was a relentless adversary, affecting millions of women worldwide. Dr. Laura Esserman, a distinguished oncologist, emerged as a beacon of hope in the battle against this formidable disease. Driven by her unwavering commitment to improving outcomes for breast cancer patients, she embarked on a mission to transform breast cancer care. Dr. Esserman's unique background as both a clinician and researcher provided her with invaluable insights. She saw the urgent need to revolutionize the traditional clinical trial model, which often moved at a snail's pace. Her vision and dedication paved the way for a groundbreaking study that would leave an indelible mark on the clinical trial industry. The I-SPY 2 Trial: An Innovation in Design : The I-SPY 2 Trial was no ordinary clinical trial; it was a groundbreaking endeavor characterized by its innovative and adaptive design. Here's why it became a game-cha...

  Clinical research in India has witnessed substantial growth in recent years, with Site Management Organizations (SMOs) playing a pivotal role in conducting trials efficiently. However, challenges arise when dealing with unorganized SMOs, which lack regulatory oversight and financial transparency. This case study explores the issues stemming from such SMOs and offers a comprehensive strategy to mitigate risks and ensure successful clinical trials in India. Understanding the Unorganized SMO Landscape :  Insights into the Growth of Unorganized SMOs in India and the Reasons Behind Their Frequent Closure: The landscape of Site Management Organizations (SMOs) in India has witnessed exponential growth in recent years, with multiple SMOs often operating within a single research site. This proliferation can be attributed to several factors, primarily the absence of robust regulatory oversight and accountability mechanisms specific to SMOs in the clinical research ecosystem.  Lac...

Nobody knows everything: Nobody knows everything, not even the CEO. Need to incorporate information from many sources. Instead, the information is distributed asymmetrically across the team and across the company. In this process, we have got to gather it and make sense of it and asking the experts is the best and fastest way to do that. With luck, we chose our work because of bold vision. We want to deliver that vision to the world whether it is a message or service or an experience software or even a story or an idea. But bringing a vision to life is difficult. It I s always easy to get in endless emails, deadline that slip, meeting that burn up day, a long term projects based on questionable assumptions. It does not have to be that way. If there is any idea, big challenge and not quite enough time and if we could not prove that idea was viable in that time, then it switches to different projects/ideas. We need encouragement in Clinical Trial industry on experiment not only in th...

Process improvement techniques increasingly have been applied outside manufacturing for examples software development and healthcare . I Concerns the potential use of lean and six sigma to improve the process involved in clinical research. Improving quality, avoiding delays and errors and speeding up the time to implementation of biomedical discoveries is primary objective. Reducing the time between biomedical research discoveries and their adoption into clinical practice requires increased co-ordination, systematic planning. Better co-ordination, timeliness, efficiency and value of clinical research can be achieved by applying the set of principles, practices and method represented by Lean and Six sigma. Lean thinking involves a set of principles, practices and methods or designing, improving and managing process. Lean process reflects the goal of continually reducing waste and improving work flow to efficiently produce a product or service that is received to be or high val...